HARP News and Press, Harpoon Therapeutics Inc. From 09/28/21

Sonoma Pharmaceuticals (NASDAQ:SNOA) +70% on product launch in U.S. and Europe Planet Green (NYSE:PLAG) +30%. ZIVO Bioscience (NASDAQ:ZIVO) +20%. Frequency Electronics (NASDAQ:FEIM) +17% wins contract from the Office of Naval Research for atomic clock development AGM Group...

Harpoon Therapeutics, Inc. stock is down over 55% since it released data on its most advanced early-stage program (HPN424 for metastatic castration-resistant prostrate cancer) in June 2020. The company has a total of four early-stage programs, the most important of which is HPN217, in...

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate ...

Harpoon Therapeutics (NASDAQ:HARP): Q2 GAAP EPS of -$0.52 misses by $0.09. Revenue of $5.8M (+110.1% Y/Y) misses by $1.19M. Harpoon ended the second quarter of 2021 with $175.2M in cash, cash equivalents, and marketable securities compared to $150.0M as of December 31, 2020.  Press Relea...

Presented updated interim Phase 1/2a clinical trial data for PSMA-targeting TriTAC ® HPN424 in prostate cancer at ASCO Annual Meeting Provided clinical trial updates for three additional TriTAC programs and ProTriTAC platform SOUTH SAN FRANCISCO, Calif., A...

Shares of Harpoon Therapeutics Inc. (NASDAQ:HARP) traded at a new 52-week low today of $9.95. Approximately 159,000 shares have changed hands today, as compared to an average 30-day volume of 503,000 shares. Based on a current price of $10.24, Harpoon Therapeutics Inc. is currently 37.8%...

Cullinan is building a unique hub-and-spoke business model in drug development to build more efficient and scalable pipelines. The company has already built out a pipeline of 7 assets and got the model off the ground to prove that they can structure their pipeline based on opportunist...

Photo by goir/iStock via Getty Images Merus jumps on Citi upgrade Merus (MRUS) shares have climbed ~5.4% in early trading after Citi analyst Yigal Nochomovitz upgraded the stock to buy from neutral. The price target of $31.00 per share implies a premium of ~49.9%. Citing dataset pre...

Three TriTAC clinical programs (HPN424, HPN536 and HPN328) have shown tumor size reductions or stable disease, and meaningful treatment duration All four clinical programs demonstrate half-life extension, target engagement and T cell activation Cytokine release syndrome ob...

Gainers: SemiLEDs (LEDS) +66%.Senseonics (SENS) +49%.Windtree Therapeutics (WINT) +38%.MoSys (MOSY) +34%.Ra Medical Systems (RMED) +29%.LightPath Technologies (LPTH) +27%.American Superconductor (AMSC) +26%.Smart Sand (SND) +25%.The9 (NCTY) +24%.Vinco Ventures (BBIG) +22%....